Tricuspid regurgitation echocardiography

Tricuspid Regurgitation Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Tricuspid Regurgitation from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Stages
History and Symptoms
Physical Examination
Laboratory Findings
Echocardiography
Chest X Ray
Electrocardiogram
Cardiac Stress Test
Cardiac MRI
Cardiac Catheterization
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical therapy
Surgery
Primary Prevention
Secondary Prevention
Case Studies
Case #1
Tricuspid regurgitation echocardiography On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Tricuspid regurgitation echocardiography All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA onTricuspid regurgitation echocardiography
CDC on Tricuspid regurgitation echocardiography
Tricuspid regurgitation echocardiography in the news
Blogs on Tricuspid regurgitation echocardiography
Directions to Hospitals Treating Tricuspid regurgitation
Risk calculators and risk factors for Tricuspid regurgitation echocardiography

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Overview

Transthoracic echocardiography (TTE) should be performed in a patient with suspected tricuspid regurgitation to confirm the diagnosis, determine the etiology, and to establish the baseline severity of disease.

Echocardiography

Transthoracic eschocardiogrpahy (TTE) is the diagnostic modality of choice to evaluate tricuspidregurgitation. TEE allows the evaluation of the following:

• Right ventricle structure and function
• Right atrium structure and function
• Inferior vena cava
• The structure and function of the left chambers of the heart
• The structures of the tricuspid valve and the underlying etiology of mitral regurgitation
• Pulmonary artery pressure
• Pressures in the heart chambers
• The severity of the tricuspid regurgitation through the measurement of:
  • The trucuspid annular diameter in the apical 4-chamber view
  • Tricuspid valve leaflet tethering height
  • Tricuspid valve leaflet tethering area

When TTE is non diagnostic, transesophageal echocardiography (TEE) may be performed. However, TEE is not provide an optimal way to assess the tricuspid valve.

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary

Class I

"1. TTE is indicated to evaluate severity of TR, determine etiology, measure sizes of right-sided chambers and inferior vena cava, assess RV systolic function, estimate pulmonary artery systolic pressure, and characterize any associated left-sided heart disease. (Level of Evidence: C)"

Class IIb

"1. CMR or real-time 3-dimensional echocardiography may be considered for assessment of RV systolic function and systolic and diastolic volumes in patients with severe TR (stages C and D) and suboptimal 2-dimensional echocardiograms. (Level of Evidence: C)"

2008 ACC/AHA Guidelines for the Management of Patients with Valvular Heart Disease - Evaluation of Tricuspid Valve Disease in Adolescents and Young Adults(DO NOT EDIT)

Class I

"1. Doppler echocardiography is indicated for the initial evaluation of adolescent and young adult patients with TR, and serially every 1 to 3 years, depending on severity. (Level C)"

Sources

• 2008 ACC/AHA Guidelines incorporated into the 2006 guidelines for the management of patients with valvular heart disease